Epic Bio

31 articles about Epic Bio

• Epic Bio to Participate in a Fireside Chat at the Canaccord Genuity Genetic Medicine for Generalists

  4/10/2024

  Epic Bio, a leading epigenetic editing company that plans to have its FSHD program enter the clinic this year, today announced that Amber Salzman, Ph.D., chief executive officer, participated in a fireside chat at the Canaccord Genuity - Genetic Medicine for Generalists Fireside Chat today.

• Epic Bio Announces Robust Slate of Presentations at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting

  4/9/2024

  Epic Bio, a leading epigenetic editing company that plans to have its FSHD program enter the clinic this year, today announced the acceptance of six abstracts, three oral presentations, and three poster presentations at the upcoming Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), taking place May 7-11, 2024, in Baltimore, Maryland.

• Epic Bio to Participate in a Fireside Chat at the Cantor Virtual Muscular Dystrophy Symposium

  4/1/2024

  Epic Bio, a leading epigenetic editing company that plans to dose its first patients later this year, today announced that Amber Salzman, Ph.D., chief executive officer, will participate in a fireside chat at the Cantor Virtual Muscular Dystrophy Symposium at 9:40 a.m. PT, Tuesday, April 2, 2024.

• 

  Epigenetic Editing Explodes on the Heels of Gene Editing Success

  3/25/2024

  Ubiquitous potential, possible safety advantages and the recent growth of cell and gene therapy are driving investment in a different type of genetic editing.

• Epic Bio to Present at the Upcoming Charles River Cell and Gene Therapy Summit

  3/13/2024

  Epic Bio, a leading epigenetic editing company that plans to dose its first patients later this year, today announced that Amber Salzman, Ph.D., chief executive officer, will present at the Charles River Cell & Gene Therapy Summit at 2:00 p.m. PT, Tuesday, March 19, 2024, in South San Francisco, Calif.

• Epic Bio to Present at the Upcoming CRISPR2.0 Conference

  11/21/2023

  Epic Bio announced a presentation at the upcoming CRISPR2.0 conference being held November 28-30, 2023, at the Hilton Boston Back Bay, Boston Massachusetts.

• FDA Grants Orphan Drug Designation to EPI-321, Epic Bio's Novel Genetic Medicine Candidate for Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)

  11/16/2023

  Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to EPI-321 for the treatment of facioscapulohumeral muscular dystrophy (FSHD), the most common form of muscular dystrophy in adults.

• Epic Bio to Participate in Upcoming November 2023 Investor Conference

  11/7/2023

  Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, announced that the management will participate in an upcoming investor conference.

• Epic Bio Reports New Data on Hypercompact Cas Proteins Optimized for Broad Therapeutic Applicability

  10/26/2023

  Epic Bio is presenting new data reflecting advances in its Gene Expression Modulation System (GEMS) platform, alongside additional preclinical data supporting the company’s lead program, EPI-321, in development for the treatment of facioscapulohumeral muscular dystrophy (FSHD).

• Epic Bio to Present at the Upcoming Annual European Society of Gene and Cell Therapy

  10/19/2023

  Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, announced four poster presentations at the upcoming European Society of Gene and Cell Therapy taking place October 24-27, 2023, in Brussels, Belgium.

• Epic Bio Announces the Appointment of Weston Miller, M.D., as Chief Medical Officer

  10/17/2023

  Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, announced that Weston Miller, M.D., will join the company as chief medical officer effective October 23, 2023.

• Epic Bio to Present at the Upcoming BMO Life Sciences Private Company Showcase

  10/5/2023

  Epic Bio today announced that Amber Salzman, Ph.D., chief executive officer, will present at the BMO Fall Private Company Showcase being held Thursday, October 12, 2023, New York, NY.

• Epic Bio to Present Preclinical Data at 28th International Annual Congress of the World Muscle Society

  9/28/2023

  Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today announced an oral and poster presentation at the upcoming International Annual Congress of the World Muscle Society taking place October 3-7, 2023 in Charleston, South Carolina.

• Epic Bio to Present at Upcoming BMO Biopharma Spotlight Series Event

  9/19/2023

  Epic Bio today announced that Amber Salzman, Ph.D., chief executive officer, will participate in a panel discussion at the BMO Biopharma Spotlight Series.

• Epic Bio Reports Discovery of Exceptionally Durable Gene Activators and Creation of Machine Learning Algorithm to Design New Activators

  9/14/2023

  Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today announced data supporting the breakthrough potential of its Gene Expression Modulation System (GEMS) platform for epigenetic engineering.

• Epic Bio Named a “Fierce 15” Company by Fierce Biotech

  8/28/2023

  Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, has been named to Fierce Biotech’s 2023 “Fierce 15” list, designating it as one of the most outstanding early-stage biotechnology companies in the industry.

• Epic Bio Presents New Data on Epigenetic Editing Platform at CRISPR Frontiers Conference

  8/17/2023

  Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today presented new data on its epigenetic editing platform at Cold Spring Harbor Laboratory’s Genome Engineering: CRISPR Frontiers conference, being held August 16-20, 2023, in Cold Spring Harbor, NY.

• Epic Bio Presents Compelling Preclinical Data Supporting Clinical Initiation of EPI-321 for FSHD

  6/16/2023

  Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, presented new non-human primate data supporting the clinical advancement of EPI-321 for the treatment of facioscapulohumeral muscular dystrophy.

• Epic Bio to Participate in a Fireside Chat at the Stifel Genetic Medicines Day 2023

  5/23/2023

  EPIC BIO today announced Amber Salzman, chief executive officer, and Alexandra Collin de l’Hortet, Ph.D., head of therapeutics will participate in a Fireside Chat at the Stifel Genetic Medicines Day on Tuesday, May 30, 2023, at 1:15 p.m. ET.

• Epic Bio Presents Preclinical Data on EPI-321 for Facioscapulohumeral Muscular Dystrophy at ASGCT 26th Annual Meeting

  5/19/2023

  Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, presented promising preclinical data supporting development of EPI-321 for the treatment of facioscapulohumeral muscular dystrophy.